Kraus, Fabian B. T.
Topalov, Nicole E.
Deuster, E.
Hysenaj, I.
Mayr, D.
Chelariu-Raicu, A.
Beyer, S.
Kolben, T.
Burges, A.
Mahner, S.
Trillsch, F.
Jeschke, U.
Czogalla, B.
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 18 April 2022
Accepted: 6 June 2022
First Online: 25 June 2022
Declarations
:
: TK holds stock of Roche AG. AB has received advisory board and honoraria from AstraZeneca, Clovis, Roche and Tesaro. Research support, advisory board, honoraria and travel expenses from AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, Tesaro have been received by SM. FT reports grants and personal fees from AstraZeneca, Clovis, Eisai, Medac, MSD, PharmaMar, Roche, and Tesaro/GSK, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki (1975). Approval was granted by the Ethics Committee of the Ludwig-Maximilians-University Munich (approval number 227–09, 18–392 and 19–972).